Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
None (17) ·
Aptiom (1) ·
Banzel (1) ·
Briviact (1) ·
Cerebyx (1) ·
Depakote (1) ·
Diacomit (1) ·
Dilantin (1) ·
DXM (1) ·
DXO (1) ·
Epidiolex (1) ·
Felbatol (1) ·
Fintepla (1) ·
Fycompa (1) ·
Gabitril (1) ·
Lithobid (extended-release); Eskalith (discontinued in US); Carbolith (Canada); Priadel (UK); Camcolit (UK) (1) ·
Luminal (1) ·
Onfi (1) ·
Sabril (1) ·
Spravato (1) ·
Vimpat (1) ·
Xcopri (1) ·
Zarontin (1) ·
Zonegran (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
Active metabolite of DXM; NMDA antagonist (1) ·
AMPA receptor antagonist (1) ·
Contains salvinorin A (1) ·
GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) ·
GABA reuptake inhibitor (GAT-1 blocker) (1) ·
GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) ·
GABAA potentiator and direct activator (1) ·
Irreversible GABA-T inhibitor (1) ·
Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) ·
Kappa-opioid receptor agonist (1) ·
Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) ·
NMDA antagonist (3) ·
NMDA antagonist; endogenous opioid releaser (1) ·
NMDA antagonist; fluorinated ketamine analogue (1) ·
NMDA antagonist; GABAA potentiator (1) ·
NMDA antagonist; kappa-opioid agonist (1) ·
NMDA antagonist; ketamine analogue (1) ·
NMDA antagonist; more stimulating than PCP (1) ·
NMDA antagonist; opioid agonist (1) ·
NMDA antagonist; potent opioid agonist (1) ·
NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) ·
NMDA antagonist; sigma receptor agonist (2) ·
NMDA antagonist; sigma receptor agonist; dopaminergic (1) ·
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) ·
Prodrug of phenytoin; sodium channel blocker (1) ·
Serotonin releaser; sigma-1 agonist (1) ·
Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) ·
Sodium channel blocker (2) ·
Sodium channel blocker; GABAA positive allosteric modulator (1) ·
Sodium channel modulator (1) ·
Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) ·
SV2A ligand (higher affinity than levetiracetam) (1) ·
T-type calcium channel blocker (1)
uses:
starting dose:
preparations:
None (38) ·
28 mg/device (each dose uses 2 devices) (1) ·
Lithium carbonate: immediate-release capsules (150 mg, 300 mg, 600 mg) and tablets (300 mg); extended-release tablets (300 mg, 450 mg). Lithium citrate: oral solution (8 mEq/5 mL, equivalent to 300 mg lithium carbonate per 5 mL) for patients unable to swallow tablets. (1)
fda max:
onset:
None (38) ·
Antimanic effects begin within 5-7 days of reaching therapeutic serum levels, with full response often requiring 2-3 weeks. For acute mania, a neuroleptic is typically added for rapid sedation while lithium takes effect.'"`UNIQ--ref-00000053-QINU`"' (1) ·
Within hours of first administration (1)
halflife:
bioavailability:
pregnancy:
legal:
None (38) ·
Not a controlled substance in the United States, European Union, United Kingdom, Canada, or Australia. Prescription-only in all of these jurisdictions due to the narrow therapeutic index and the need for serum monitoring. No abuse potential has been identified. (1) ·
Rx, Schedule III (US). REMS program required. (1)
Showing below up to 40 results in range #1 to #40.